Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Surfactants Stories

2014-03-13 08:28:38

Conference Call Today, March 13, 2014 at 10:00 a.m. ET WARRINGTON, Pa., March 13, 2014 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced financial results for the fourth quarter ended December 31, 2013, as well as recent business updates. The Company will host a conference call today, March 13, 2014 at 10:00 AM ET. Conference call details are below. Key highlights...

2014-03-11 08:29:57

WARRINGTON, Pa., March 11, 2014 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, will report fourth quarter 2013 financial results on Thursday, March 13, 2014 before the open of the U.S. financial markets. The Company will host a conference call and live audio webcast at 10:00 a.m. Eastern Time that same day. During the conference call, Discovery Labs' management will...

2013-11-21 08:27:11

WARRINGTON, Pa., Nov. 21, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that management will present an overview and update on the Company's business at the 25(th) Annual Piper Jaffray Health Care Conference on Tuesday, December 3, 2013 at 1:10 PM ET. The conference will be held at the New York Palace Hotel in New York, New York. Discovery...

2013-11-12 16:26:01

WARRINGTON, Pa., Nov. 12, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's investigational new drug (IND) application for AEROSURF(®) and the Company can initiate its phase 2 clinical program. The phase 2 clinical program is expected to include two studies. The primary goal...

2013-11-08 08:28:08

WARRINGTON, Pa., Nov. 8, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, will host a conference call at 10:00 a.m. ET on Wednesday, November 13, 2013 to discuss the third quarter financial results and other business updates. A question-and-answer session will follow managements' remarks. The Company will report third quarter 2013 results on Tuesday, November 12,...

2013-11-08 08:27:43

WARRINGTON, Pa., Nov. 8, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that it has initiated the U.S. commercial launch of SURFAXIN(® )(lucinactant) Intratracheal Suspension for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS. SURFAXIN is the first FDA-approved synthetic, peptide-containing...

2013-10-11 23:20:14

Surfactants Market report explains qualitative and quantitative aspects of surfactants such as synthetic and bio-based or anionic, non-ionic, cationic, and amphoteric also briefly explains the consumption of the surfactant market by type and by geography. http://www.marketsandmarkets.com/Market-Reports/biosurfactants-market-493.html (PRWEB) October 11, 2013 The report “Surfactants Market by Product Types (Anionic, Non-Ionic, Cationic, Amphoteric), Substrates (Synthetic/Petrochemical,...

2013-10-08 08:28:53

WARRINGTON, Pa., Oct. 8, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent entitled "Capillary System With Fluidic Element." The Company holds a license to this patent (U.S. Patent Application. No. 12/285,312), which will provide additional...

2013-10-04 08:23:33

Commercial Introduction of SURFAXIN Planned for the Fourth Quarter of 2013 WARRINGTON, Pa., Oct. 4, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the U.S. Food and Drug Administration (FDA) has agreed to the Company's updated product specifications for SURFAXIN(® )(lucinactant) Intratracheal Suspension which was approved for the prevention of...

2013-09-05 08:28:52

WARRINGTON, Pa., Sept. 5, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that Company management will be presenting at the Stifel Healthcare Conference 2013 at the Four Seasons Hotel in Boston, MA. The presentation is scheduled for Wednesday, September 11, 2013 at 11:30 a.m. ET. About Discovery Labs Discovery Laboratories, Inc. is a specialty...